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Abstract
Mutations in the LRRK2 kinase are the most common cause of familial Parkinson’s disease, and variants increase risk for the
sporadic form of the disease. LRRK2 phosphorylates multiple RAB GTPases including RAB8A and RAB10. Phosphorylated
RAB10 is recruited to centrosome-localized RILPL1, which may interfere with ciliogenesis in a disease-relevant context. Our
previous studies indicate that the centrosomal accumulation of phosphorylated RAB8A causes centrosomal cohesion
deficits in dividing cells, including in peripheral patient-derived cells. Here, we show that both RAB8 and RAB10 contribute
to the centrosomal cohesion deficits. Pathogenic LRRK2 causes the centrosomal accumulation not only of phosho-RAB8 but
also of phospho-RAB10, and the effects on centrosomal cohesion are dependent on RAB8, RAB10 and RILPL1. Conversely, the
pathogenic LRRK2-mediated ciliogenesis defects correlate with the centrosomal accumulation of both phospho-RAB8 and
phospho-RAB10. LRRK2-mediated centrosomal cohesion and ciliogenesis alterations are observed in patient-derived
peripheral cells, as well as in primary astrocytes from mutant LRRK2 mice, and are reverted upon LRRK2 kinase inhibition.
These data suggest that the LRRK2-mediated centrosomal cohesion and ciliogenesis defects are distinct cellular readouts of
the same underlying phospho-RAB8/RAB10/RILPL1 nexus and highlight the possibility that either centrosomal cohesion
and/or ciliogenesis alterations may serve as cellular biomarkers for LRRK2-related PD.
Human Molecular Genetics, 2019, Vol. 28, No. 21 3553
Introduction
Autosomal-dominant point mutations in the leucine-rich repeat
kinase 2 (LRRK2) gene are the most common cause of familiar
Parkinson’s disease (PD), and protein coding as well as non-
coding variants at the LRRK2 locus are major genetic suscep-
tibility factors for sporadic PD (1). These genetic findings point
towards a key role for LRRK2 in the entire PD disease spectrum.
Recent mass spectroscopy studies have revealed that LRRK2 is
able to phosphorylate a small subset of RAB proteins in vitro
and in vivo (2–5), with their phosphorylation enhanced by all
pathogenic LRRK2 mutants in a cellular context (3). Current
data suggest that RAB8 and RAB10 serve as the most prominent
LRRK2 kinase substrates, and their phosphorylation is detectable
in various cells and tissues including brain (6–8). Therefore, and
given the relevance of LRRK2 for PD, it is crucial to determine
the cellular processes which are most significantly affected by
an increase in LRRK2 kinase activity via RAB8 and/or RAB10
phosphorylation.
RAB GTPases are key regulators of all eukaryotic vesicular
membrane–trafficking events (9,10). LRRK2 phosphorylates
a crucial region within RAB proteins, whose conformation
changes dependent on the nucleotide-bound state. Effectors and
regulatory proteins interact with RAB proteins in a nucleotide-
dependent manner through this region, and phosphorylation
interferes with the ability of the RABs to bind to most of these
proteins (3). This is expected to lead to a loss of function in
terms of RAB-mediated membrane-trafficking events, as we
have recently shown for the LRRK2-mediated phosphorylation
of RAB8A (11).
Recent studies also highlight additional, gain-of-function
mechanisms for phosphorylated RAB8 and RAB10. Our data
show that phosphorylated RAB8A accumulates in a pericen-
trosomal/centrosomal area to cause deficits in centrosomal
positioning with effects on neurite outgrowth, cell polarization
and directed migration (12), all cellular phenotypes previously
reported to be impaired by pathogenic LRRK2 (13–18). The
LRRK2-mediated pericentrosomal/centrosomal accumulation of
phospho-RAB8 further causes deficits in centrosomal cohesion
in dividing cells, including peripheral LRRK2 PD patient-derived
cells, in a manner dependent upon LRRK2 kinase activity
(12). Surprisingly, whilst the phosphorylated RABs lose their
interactions with their effector and regulatory proteins, they
were reported to specifically gain the ability to interact with
RILPL1 (2), a poorly characterized protein which localizes to the
mother centriole and regulates ciliogenesis (19). The primary
cilium emerges from the basal body, which is a special form of
the mother centriole, and a recent study reports that pathogenic
LRRK2 interferes with ciliogenesis in a manner dependent on
both phospho-RAB10 and RILPL1 (20). Ciliogenesis deficits were
observed in various cell types, including the somatosensory
cortex and the small population of cholinergic neurons present
in the striatum of LRRK2 transgenicmice (20). The latter neurons
require cilia to sense Sonic hedgehog signalling (21,22), which
provides a neuroprotective circuit to support dopaminergic
neurons (23). In thismanner, ciliogenesis deficitsmay contribute
to PD pathogenesis in a non-cell-autonomousmanner. However,
it remains unknown whether the reported LRRK2-mediated
centrosomal and ciliogenesis deficits are distinct cellular
reflections of the same phospho-RAB8/10-RILPL1 pathway.
Here, we show that centrosomal cohesion deficits are
mediated by both RAB8A/B and RAB10 and correlate with the
centrosomal accumulation of both phospho-RAB proteins. The
pathogenic LRRK2-mediated centrosomal cohesion alterations
are abolished in RAB8A, RAB10 or RILPL1 knockout cells. In
addition, the pathogenic LRRK2-mediated ciliogenesis deficits
also correlate with the centrosomal accumulation of phospho-
RAB8/10. Both centrosome-related deficits can be observed in
LRRK2 PD patient-derived peripheral cells as well as in primary
astrocytes from pathogenic LRRK2 knockin mice. These data
suggest that these LRRK2-mediated deficits are distinct cellular
readouts of the same underlying RAB8/RAB10/RILPL1 nexus and
highlight the possibility that either centrosomal cohesion and/or
ciliogenesis alterations may serve as cellular biomarkers for
LRRK2-related PD.
Results
Both RAB8A/B and RAB10 cause centrosomal cohesion
deficits when co-expressed with wild-type LRRK2
We first wondered whether the centrosomal cohesion deficits
induced upon co-expression of wild-type LRRK2 with RAB8A (12)
are dependent on the RAB8A prenylation status, since preny-
lation is known to increase the affinity of RAB proteins for
membranes and is required for their function (24). We mutated
the residue required for prenylation and confirmed that the
RAB8A-C204A mutant was diffusely distributed as in contrast
to wild-type RAB8A when expressed in HeLa cells, consistent
with the intended effect of the mutation in blocking prenyla-
tion (Fig. S1A,B). Whilst expression of either RAB8A or LRRK2
on their own was without effect, co-expression of both caused
centrosomal cohesion deficits, which was not observed when
co-expressing LRRK2 with RAB8A-C204A (Fig. 1A), even though
both wild-type and prenylation-deficient RAB8A mutants were
expressed to similar degrees (Fig. 1B). Interestingly, and as previ-
ously described for RAB10 (25), only wild-type but not RAB8A-
C204A was phosphorylated by LRRK2 (Fig. 1B), indicating that
RAB8A needs to be prenylated to be phosphorylated, so as to
then cause the resultant LRRK2-mediated effects on centrosome
cohesion.
LRRK2 phosphorylates both the A and B isoforms of RAB8
(2,3). These isoforms are encoded by different genes, are highly
similar in sequence, but display differential tissue-specific
expression patterns (26), and their functions are not redundant
in all cases (27,28). We therefore next analyzed whether RAB8B
may play similar roles in modulating the LRRK2-mediated
centrosomal cohesion deficits. Indeed, when co-expressed with
wild-type LRRK2, RAB8B caused cohesion deficits identical to
those observed for RAB8A, which were not observed with a
phosphorylation-deficient RAB8B-T72A mutant (Fig. 1C and D).
Both wild-type and mutant RAB8B were expressed to similar
degrees and localized to a perinuclear tubular-like compartment
like RAB8A, but additional cytosolic localization was observed
with the phosphorylation-deficient RAB8B mutant (Fig. S1A,B).
As an additional means to assure that the effects were mediated
by the LRRK2 kinase activity, we employed the LRRK2 kinase
inhibitor GSK2578215A, which largely reverted the centrosomal
cohesion deficits in the presence of LRRK2 and RAB8B (Fig. 1D).
Thus, both RAB8A and RAB8B cause centrosomal cohesion
deficits in a manner dependent on the LRRK2 kinase activity.
RAB10 has been identified as another prominent LRRK2
kinase substrate (2,3), and both RAB8 and RAB10 have been
reported to be involved in centrosome-related events (27).
These findings prompted us to analyze for the effects of RAB10
expression on centrosomal alterations in the presence of wild-
type LRRK2. Co-expression of wild-type LRRK2 with RAB10, but
not a phosphorylation-deficient RAB10-T73A mutant, caused
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Figure 1. Expression of prenylation-competent RAB8A, or of RAB8B or RAB10with LRRK2, causes centrosomal cohesion deficits in amanner dependent on LRRK2 kinase
activity. (A) Quantification of the percentage of cells with split centrosomes (duplicated centrosomes with a distance between their centres > 1.5 μm) in HEK293T cells
transfected with the different constructs as indicated. Bars represent mean ± s.e.m. (n=3 experiments); ∗∗∗∗ , P< 0.001. (B) Left: HEK293T cells were co-transfected with
either wild-type LRRK2 and RAB8A, or RAB8A-C204A as indicated, and extracts blotted for LRRK2 levels, RAB8A levels, phospho-RAB8A levels and tubulin as loading
control. Right: no significant differences in the levels of RAB8A or RAB8A-C204A expression. Blots of the type indicated on the left were quantified for RAB8A levels
and normalized to tubulin. Bars represent mean ± s.e.m. (n=6 experiments). (C) Example of HEK293T cells transfected with either GFP-tagged wild-type LRRK2 (wt), or
wild-type LRRK2 along with either mRFP-tagged RAB8B or phosphorylation-deficient RAB8B-T72A mutant as indicated and stained for pericentrin antibody and DAPI.
Scale bar, 5 μm. (D) Quantification of the split centrosome phenotype in cells expressing the indicated constructs, in either the absence or presence of the LRRK2 kinase
inhibitor GSK2578215A (500 nm, 2 h) before fixation. Bars represent mean ± s.e.m. (n=3 experiments); ∗∗∗∗ , P< 0.001. (E) Example of HEK293T cells transfected with
either GFP-tagged wild-type LRRK2 (wt), or wild-type LRRK2 along with either mRFP-tagged RAB10 or phosphorylation-deficient RAB10-T73A mutant as indicated and
stained for pericentrin antibody and DAPI. Scale bar, 5 μm. (F) Quantification of the centrosomal cohesion phenotype in cells expressing the indicated constructs, in
either the absence or presence of the LRRK2 kinase inhibitor GSK2578215A (500 nm, 2 h) before fixation. Bars represent mean ± s.e.m. (n=3 experiments); ∗∗∗∗, P<0.001;
∗∗∗, P<0.005.
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centrosomal cohesion deficits identical to those observed with
RAB8A or RAB8B, respectively (Fig. 1E and F). Both wild-type
and mutant RAB10 were expressed to similar degrees and
localized to a perinuclear tubular-like compartment identical
to RAB8A, with additional cytosolic localization observed
with the phosphorylation-deficient RAB10 mutant (Fig. S1A–C).
Application of the LRRK2 kinase inhibitor GSK2578215A largely
reverted the centrosomal cohesion deficits observed in the
presence of LRRK2 and RAB10 (Fig. 1F). Therefore, co-expression
of wild-type LRRK2 with either RAB8A, RAB8B or RAB10 causes
centrosomal cohesion deficits in a manner dependent on the
LRRK2 kinase activity.
Pathogenic LRRK2-induced centrosomal cohesion
deficits correlate with aberrant
pericentrosomal/centrosomal accumulation
of phospho-RAB8 and phospho-RAB10
We previously showed that the pathogenic LRRK2-induced
centrosomal cohesion deficits correlate with an aberrant
centrosomal/pericentrosomal accumulation of endogenous
phosphorylated RAB8 (12). Given that increasing RAB10 levels
also caused centrosomal cohesion deficits in the presence of
wild-type LRRK2, we wondered whether pathogenic LRRK2 may
also trigger the pericentrosomal/centrosomal accumulation of
endogenous phosphorylated RAB10.
We first analyzed for the specificity of distinct RAB8,
RAB10, phospho-RAB8 and phospho-RAB10 antibodies by
western blotting and immunocytochemistry techniques. As
assessed by western blotting, both knockout-validated sheep
and mouse total anti-RAB10 antibodies were specific for RAB10,
and both knockout-validated sheep and mouse total anti-
RAB8 antibodies were specific for RAB8, respectively (Fig. S2)
(12). By immunocytochemistry, the sheep knockout-validated
total anti-RAB10 and anti-RAB8 antibodies were also specific
for the respective RAB proteins (Fig. S3A,B). In contrast, the
sheep phospho-RAB10 antibody detected accumulation of
phosphorylated RAB species in cells expressing wild-type LRRK2
with either RAB10 or with RAB8, indicating that it was detecting
both phosphorylated RAB species, and similar results were
obtained for the sheep phospho-RAB8 antibody (Fig. S3C,D).
Since the high-affinity knockout-validated commercial rabbit
monoclonal anti-phospho-RAB10 and anti-phospho-RAB8
antibodies (6) were not suitable for immunocytochemistry
purposes under the conditions employed (Fig. S3E,F), we
used the sheep phospho-RAB10 antibody, which detects both
phosphorylated RAB10/8 (Fig. S3D), as well as the knockout-
validated mouse monoclonal anti-RAB10 antibody highly
specific for total RAB10 (Fig. S3G), for further cell biological
analysis.
Staining of HEK293T cells expressing pathogenic Y1699C
LRRK2 revealed pericentrosomal/centrosomal phospho-RAB10/8
accumulation (Fig. 2A and B). The signal was specific for
detecting the phosphorylated RAB species, as not observed
upon preincubation of the antibody with phospho-peptide
or upon treatment of cells with MLi2, another distinct and
highly specific LRRK2 kinase inhibitor (Fig. 2A and B). We
further used a knockout-validated total anti-RAB10 antibody
highly specific for RAB10 (Fig. S3G). Endogenous RAB10 was
localized to a pericentrosomal/centrosomal area in cells
expressing either pathogenic Y1699C, R1441C or G2019S
mutant LRRK2 (Fig. 2C and D). Such localization was reverted
upon application of MLi2 and was not observed in non-
transfected, wild-type LRRK2-transfected or kinase-inactive
G2019S-K1906M LRRK2-transfected cells, respectively, indi-
cating that it reflects a phosphorylated species of RAB10
(Fig. 2C and D).
The accumulation of phospho-RAB10 was next evaluated in
another cell system. The phospho-RAB10/8 antibodies were not
of sufficient affinity to detect the centrosomal accumulation of
endogenous phospho-RABs in G2019S LRRK2 mutant SH-SY5Y
cells but did detect centrosomal accumulation of phospho-
RAB10/8 when expressing wild-type RAB10 in either wild-
type or G2019S LRRK2-mutant SH-SY5Y cells to increase the
phosphorylated RAB10 species (Fig. S4A,B). The increase in
the phospho-RAB10 signal disappeared when pretreating cells
with MLi2 and was not detected when expressing the non-
phosphorylatable RAB10-T73A mutant (Fig. S4A,B), indicating
that it was specifically detecting a LRRK2-phosphorylated
version of RAB10. Expression of wild-type RAB10, but not
phosphorylation-deficient RAB10 mutant, in wild-type or
G2019S LRRK2-mutant SH-SY5Y cells caused a centrosomal
cohesion deficit which was reversed by MLi2 (Fig. S4C,D).
Therefore, as analyzed in two distinct cell systems, increasing
the pericentrosomal/centrosomal amount of phosphorylated
RAB10 also correlates with the observed centrosomal cohesion
deficits.
Pathogenic LRRK2-mediated centrosomal cohesion
deficits depend on RAB8A, RAB10 and RILPL1
To further analyze how pathogenic LRRK2 causes centrosomal
cohesion deficits, we expressed wild-type or distinct LRRK2
mutants in either wild-type A549 cells, or in cells deficient
in RAB8A, RAB10 or RILPL1. In wild-type cells, expression of
pathogenic G2019S, R1441C or Y1699C LRRK2 mutant caused
a centrosomal cohesion phenotype which was abolished
upon treatment with the LRRK2 kinase inhibitor MLi2 and
was not observed when expressing wild-type or kinase-dead
K1906M LRRK2 (Fig. 3A and B), with all constructs expressed to
similar degrees (Fig. 3C and D). We next attempted to correlate
the LRRK2-mediated centrosomal cohesion phenotype with
alterations in the levels of phospho-RAB8 or phospho-RAB10
as assessed by western blotting techniques. In non-transfected
A549 RAB8A knockout cells, the total anti-RAB8 antibody,
previously reported to be specific for RAB8(A+B) as assessed
by western blotting of RAB8A/RAB8B double-knockout mouse
extracts (27), revealed the remaining presence of RAB8B. The
rabbit monoclonal phospho-RAB8A antibody revealed the pres-
ence of a phospho-RAB band in the A549 RAB8A knockout cells,
likely based on the reported cross-reactivity of this antibodywith
other LRRK2-phosphorylated RAB substrates including RAB8B
and/or RAB10 (6) (Fig. 3C). In contrast, the mouse monoclonal
anti-RAB10 and the rabbit monoclonal anti-phospho-RAB10
antibodies were highly specific, as no signal was detected
in the A549 RAB10 knockout cells (Fig. 3D). Importantly, the
centrosomal cohesion deficits mediated by pathogenic LRRK2
correlated with increases in phospho-RAB8/phospho-RAB10
levels in amannermodulated by the LRRK2 kinase inhibitorMLi2
(Fig. 3C and D).
When analyzing the relationship between centrosomal cohe-
sion deficits and LRRK2 expression levels as measured by quan-
titative light microscopy, the percentage of split centrosomes
and the overall mean distance between duplicated centrosomes
increasedwith increasing LRRK2 expression levels until reaching
a plateau, suggesting that pathogenic LRRK2 expression causes
a concentration-dependent centrosomal cohesion deficit which
becomes saturated at higher expression levels (Fig. 3E and F).
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Figure 2. Pathogenic LRRK2 causes kinase-dependent pericentrosomal/centrosomal accumulation of endogenous phospho-RAB10/8. (A) Example of HEK293T
cells transfected with Y1699C mutant GFP-tagged LRRK2, in either the absence or presence of 100 nm of the LRRK2 kinase inhibitor MLi2 for 60 min prior to
immunocytochemistry as indicated. Cells were stained using a sheep anti-T73-phospho-RAB10 antibody preabsorbed with dephospho-peptide, an anti-pericentrin
antibody and TOPRO. Scale bar, 5 μm. (B) Quantification of the percentage of cells displaying pericentrosomal/centrosomal phospho-RAB10/8 staining colocalizing
with centrosomes within a 3 μm diameter circle in either non-transfected cells (ctrl), or in pathogenic LRRK2-transfected cells as indicated, in either the absence or
presence of antibody preabsorption with dephospho-peptide or phospho-peptide (+pp), or pretreatment of cells with MLi2 as described above. Around 100–150 cells
were quantified per condition per experiment. Bars represent mean ± s.e.m. (n=3 independent experiments); ∗∗∗∗, P< 0.001. (C) Cells were transfected with pathogenic
GFP-tagged LRRK2 and subjected to immunocytochemistry using a knockout-validated anti-RAB10 antibody, pericentrin and TOPRO upon incubation of cells with
100 nm MLi2 for 60 min prior to immunocytochemistry as indicated. Scale bar, 5 μm. (D) Quantification of the percentage of cells displaying pericentrosomal RAB10
accumulation in either non-transfected cells (ctrl), wild-type, pathogenic LRRK2, or kinase-inactive pathogenic LRRK2 (G2019S-K1906M)-transfected cells as indicated,
either in the absence or presence of MLi2 (100 nm, 1 h). Bars represent mean ± s.e.m. (n=3 independent experiments); ∗∗∗∗ , P<0.001; ∗∗∗ , P< 0.005.
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Figure 3. Pathogenic LRRK2 causes kinase-dependent and dose-dependent centrosomal cohesion deficits. (A) Example of wild-type A549 cells transfected with either
pCMV (ctrl), or with the indicated flag-tagged LRRK2 constructs and stained with an antibody against flag, pericentrin and DAPI. Scale bar, 10 μm. (B) Quantification of
the percentage of wild-type A549 cells with split centrosomes (duplicated centrosomes with a distance between their centres > 2.5 μm) transfected with the different
LRRK2 constructs, and either left untreated or incubated with 500 nm MLi2 for 2 h before immunocytochemistry as indicated. Bars represent mean ± s.e.m. (n=3
experiments); ∗∗∗∗, P< 0.001; ∗∗∗ , P<0.005; ∗, P< 0.05. (C) Wild-type A549 cells were transfected with the indicated LRRK2 constructs, either left untreated or incubated
with 500 nmMLi2 for 2 h as indicated, and extracts blotted for flag-tagged LRRK2, phosphorylated LRRK2 (phospho-S935), endogenous RAB8 (A+B), phospho-T72-RAB8A
(rabbit monoclonal antibody) and tubulin as loading control. (D) Same as in (C), but extracts blotted for flag-tagged LRRK2, phosphorylated LRRK2 (phospho-S935),
endogenous RAB10, phospho-T73-RAB10 (rabbit monoclonal antibody) and tubulin as loading control. (E) Wild-type A549 cells were transfected with the indicated
flag-tagged constructs, and the percentage of cells with split centrosomes, along with the flag staining intensity of each cell were quantified from around 100 cells
with duplicated centrosomes per condition, with fluorescence intensities grouped into distinct bins as indicated. (F) Same as in (E), but depicting the mean distance
of duplicated centrosomes against the distinct binned fluorescence intensities. (G) Same as in (F), but depicting the mean distance of duplicated centrosomes in cells
transfected with the indicated constructs irrespective of flag staining intensity. ∗∗∗ , P<0.005; ∗∗ , P<0.01; ∗, P< 0.05.
Measuring the distance between duplicated centrosomes in all
cells irrespective of protein expression levels also revealed a
significant increase in the mean distance between duplicated
centrosomes in cells expressing pathogenic LRRK2 as in contrast
to control cells, with the mean centrosomal distance in control
cells similar to what has been previously described in this cell
type (20) (Fig. 3G).
A recent report suggested that RILPL1 expression in A549
cells causes a cohesion deficit in a manner independent on
expression levels (20).When expressing either C-terminally flag-
tagged, or C-terminally or N-terminally eGFP-tagged human
RILPL1, no differences in centrosomal cohesion were observed
when quantifying the percentage of split centrosomes or the
mean distance between duplicated centrosomes, including in
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cells expressing very high levels of RILPL1 (Fig. 4A, B and C).
Thus, our data indicate that pathogenic LRRK2 causes centro-
somal cohesion deficits in a concentration-dependent manner,
which is not observed upon human RILPL1 expression.
To address whether the LRRK2-mediated centrosomal
cohesion deficits are dependent on the presence of RAB8A,
RAB10 or RILPL1, we employed A549 cells where the proteins
were knocked out using CRISPR-Cas9 (20). Non-transfected A549
cells lacking RAB8A,RAB10 or RILPL1 did not display centrosomal
cohesion deficits (Fig. 4D), with the lack of the respective
proteins confirmed by western blotting techniques (Fig. S5). In
addition, no alterations were found in the levels of RAB8B in
either the RAB8A or RAB10 knockout cells, in the levels of RAB8A
in the RAB10 or RILPL1 knockout cells, or in the levels of RAB10
in the RAB8A or RILPL1 knockout cells, respectively (Fig. S5).
Importantly though, and as in contrast to A549 wild-type
cells, the pathogenic LRRK2-mediated centrosomal cohesion
deficits were drastically reduced in cells deficient for RAB8A
(Fig. 4D and E) and abolished in cells deficient for RAB10 or
RILPL1 (Fig. 4D, F and G), respectively, even though the various
LRRK2 variants were expressed to similar degrees (Fig. 4H).
Therefore, the LRRK2-mediated centrosomal cohesion deficit
is crucially dependent on RAB8A, RAB10 and RILPL1.
Pathogenic LRRK2 causes ciliogenesis deficits
associated with the pericentrosomal/centrosomal
accumulation of phospho-RAB10/8
We next aimed to determine whether the pericentrosomal/cen-
trosomal accumulation of phospho-RAB10/8, shown to interfere
with centrosomal cohesion in dividing cells,may also be respon-
sible for the reported LRRK2-mediated ciliogenesis deficits (20).
HEK293T cells were transfected with either wild-type, kinase-
inactive or pathogenic mutant LRRK2 constructs, and the per-
centage of ciliated cells quantified in both serum-fed as well
as serum-starved conditions (Fig. 5A, B and C). Serum starvation
did not increase the amount of ciliated cells (Fig. 5B and C),
likely based on the limited time of starvation possible with-
out compromising viability in this cell type. Expression of all
pathogenic LRRK2 mutants, but not of wild-type or kinase-dead
LRRK2, caused a decrease in the percentage of ciliated cells in
both serum-fed and serum-starved conditions (Fig. 5B and C).
This was associated with a significant increase in the accumu-
lation of phospho-RAB10/8 in transfected cells (Fig. 5D and E),
with all constructs expressed to similar degrees (Fig. 5F). The
phospho-RAB accumulation was reverted upon MLi2 treatment
(Fig. 5D and E), with only a slight rescue of the ciliogenesis phe-
notype observed (Fig. 5B and C), suggesting that the reformation
of cilia upon phospho-RAB10/8 removal may take additional
time.
To assure that the observed phospho-RAB accumulation
occurred at the ciliary base, cells were co-transfected with
pathogenic LRRK2 and Smoothened-EGFP (smo-EGFP) to label
cilia (Fig. 6A and B).When selectively quantifying the pathogenic
LRRK2-expressing cells still displaying cilia, phospho-RAB10/8
accumulation at/around the ciliary base could be detected, but
quantification of the fluorescence intensity of the phospho-
RAB10/8 signal indicated that there was significantly less overall
accumulation in ciliated as in contrast to non-ciliated cells, or as
in contrast to only smo-EGFP-transfected ciliated or non-ciliated
cells, respectively (Fig. 6B). Finally, when staining cells for both
ciliary and centrosomal markers, a significant percentage of the
pathogenic LRRK2-expressing cells which still contained cilia
was found to display a duplicated split centrosome phenotype
(Fig. 6C and D). Since cilia are usually reabsorbed in G2 phase
of the cell cycle (29), these data suggest that pathogenic LRRK2
may additionally interfere with proper ciliary resorption.
As another means to determine the effect of phospho-RAB
accumulation on ciliogenesis, we co-expressed wild-type LRRK2
with either RAB8A or RAB10, respectively (Fig. S6).Whilst expres-
sion of either wild-type RAB8A or wild-type RAB10 was with-
out effect on ciliogenesis, co-expression with LRRK2 caused a
deficit in ciliogenesis (Fig. S6A–C) associated with the detection
of phospho-RAB8/10 (Fig. S6D), which is analogous to what we
observed regarding centrosomal cohesion deficits (Figs 1 and
2). Altogether, these data indicate that pathogenic LRRK2 inter-
feres with both ciliogenesis and centrosome cohesion events
via the increased pericentrosomal/centrosomal accumulation of
phospho-RAB10/8.
Ciliogenesis and centrosomal cohesion deficits
in human dermal fibroblasts from G2019S LRRK2
patients and murine G2019S knockin astrocytes
Our previous studies reported centrosomal cohesion deficits in
human dermal fibroblasts from G2019S LRRK2 patients as in
contrast to healthy controls, which were reverted upon addi-
tion of LRRK2 kinase inhibitor (12). We thus wondered whether
these patient-derived cells also display a ciliogenesis phenotype.
Under serum-fed conditions, G2019S LRRK2-PD fibroblasts dis-
played a ciliogenesis deficit as in contrast to healthy control
fibroblasts (Fig. 7A and B). In this cell type, starvation promi-
nently induced ciliogenesis (Fig. 7B), and the deficit in cilio-
genesis in the pathogenic LRRK2-expressing cells as in con-
trast to control cells was also observed under starvation condi-
tions (Fig. 7B). Application of LRRK2 kinase inhibitor MLi2 had a
minor effect in rescuing such deficit, even though some fibrob-
last cells responded better than others. Further, quantification
of cilia length did not show drastic differences between con-
trol and G2019S LRRK2-PD fibroblasts (Fig. 7C and D), in agree-
ment with what has been previously described for cilia in iPSCs
from LRRK2-PD patients, or in the cortex of pathogenic LRRK2-
expressing mice (20).
Finally, we analyzed for both centrosomal cohesion and cil-
iogenesis deficits in primary mouse astrocytes cultured from
either control or G2019S knockin mice (30). Cells were stained
with GFAP, and centrosomal cohesion deficits quantified in both
the absence and presence of starvation (Fig. 8A, B and C). G2019S
knockin astrocytes displayed a centrosomal cohesion deficit as
assessed by quantifying either the percentage of split centro-
somes or the mean distance between duplicated centrosomes,
and such cohesion deficit was reverted upon application of
LRRK2 kinase inhibitor MLi2 (Fig. 8B and C). Similarly, G2019S
knockin astrocytes displayed a significant deficit in ciliogenesis
as in contrast to control cells under serum-fed conditions,which
was reverted by MLi2 (Fig. 8D and E). Thus, pathogenic LRRK2
causes both centrosomal cohesion and ciliogenesis deficits in a
disease-relevant cell type (31,32), and in a manner mediated by
the LRRK2 kinase activity.
Discussion
We have shown here that pathogenic LRRK2 causes the
pericentrosomal/centrosomal accumulation of phospho-RAB8
as well as of phospho-RAB10, and centrosomal cohesion deficits
in a manner dependent on RAB8, RAB10 and RILPL1. RAB8 and
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Figure 4. Pathogenic LRRK2-mediated centrosomal cohesion deficits depend on RAB8A, RAB10 and RILPL1. (A) Wild-type A549 cells were transfected with either
C-terminally flag-tagged or eGFP-tagged human RILPL1, or N-terminally eGFP-tagged human RILPL1, and the percentage of cells with split centrosomes, along with
the flag staining intensity (or eGFP fluorescence intensity) of each cell quantified from around 100 cells with duplicated centrosomes per condition, with fluorescence
intensities grouped into distinct bins as indicated. (B) Same as in (A), but depicting themean distance of duplicated centrosomes against the distinct binned fluorescence
intensities. (C) Same as in (B), but depicting the mean distance of duplicated centrosomes in cells transfected with the indicated constructs irrespective of flag
staining/eGFP fluorescence intensity. (D) Quantification of the mean distance of duplicated centrosomes from either wild-type A549 cells (ctrl), or A549 cells in which
the different proteins were knocked out using CRISPR-Cas9 (RAB8A-KO, RAB10-KO, RILPL1-KO), in the absence or presence of Y1699C pathogenic LRRK2 expression as
indicated. Between 50 and 100 cells with duplicated centrosomes per condition were analyzed. ∗∗∗, P< 0.005; ∗ , P< 0.05. (E) Quantification of the percentage of RAB8A
A549 knockout cells transfected with the different LRRK2 constructs displaying duplicated split centrosomes, in either the presence or absence of MLi2 (500 nm, 2 h) as
indicated. Bars represent mean ± s.e.m. (n=3 experiments); ∗, P< 0.05. (F) Quantification of the percentage of RAB10 A549 knockout cells transfected with the different
LRRK2 constructs displaying duplicated split centrosomes, in either the presence or absence of MLI2 (500 nm, 2 h). Bars represent mean ± s.e.m. (n=3 experiments).
(G) Quantification of the percentage of RILPL1 A549 knockout cells transfected with the different LRRK2 constructs displaying duplicated split centrosomes, in either
the presence or absence of MLI2 (500 nm, 2 h). Bars represent mean ± s.e.m. (n=3 experiments). (H) The distinct A549 knockout cells were transfected with the indicated
flag-tagged LRRK2 constructs, and extracts blotted for flag and tubulin as loading control.
RAB10 share various effector proteins, and the phosphorylation
by pathogenic LRRK2 kinase interferes with the ability of most
of these effector proteins to interact with the phosphorylated
RABs (3). This is expected to lead to a loss of function in the
membrane-trafficking pathways these specific RAB-effector
complexes are involved in. However, a very small amount of
effector proteins including RILPL1 behave in the opposite way by
binding to only the phosphorylated forms of RAB8 and RAB10 (2).
These unusual phospho-RAB-specific effectors are therefore of
crucial importance to understand the downstream physiological
consequences of hyperactivated LRRK2 kinase underlying PD in
a possibly neomorphic, gain-of-function manner.
RILPL1 localizes to a pericentriolar compartment adjacent to
the mother centriole and has been reported to recruit phospho-
RAB10 to this location (19,20). Under conditions of endogenous
protein expression, pathogenic LRRK2-mediated ciliogenesis
defects were rescued upon knockdown of either RAB10 or
RILPL1 (20). Similarly, we here describe that the pathogenic
LRRK2-mediated centrosomal cohesion deficits are largely
and/or completely abolished in cells lacking RAB8A, RAB10 or
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Figure 5. Pathogenic LRRK2 causes ciliogenesis deficits in a kinase-dependent manner. (A) Example of HEK293T cells transfected with either pCMV (ctrl), or with GFP-
tagged wild-type or pathogenic Y1699C constructs, and stained with an antibody against polyglutamylated tubulin, sheep anti-phospho-T73-RAB10 and DAPI. Scale bar,
10 μm. (B) HEK293T cellswere transfectedwith the indicated LRRK2 constructs, and either left untreated or treatedwithMLi2 (200 nm, 12 h) before immunocytochemistry
using an antibody against polyglutamylated tubulin and against phospho-T73-RAB10 as described in (A). The percentage of ciliated cells expressing the distinct
constructs was quantified from around 200 cells per condition per experiment. Bars representmean± s.e.m. (n=3 experiments); ∗∗∗∗, P< 0.001; ∗∗∗ , P< 0.005; ∗, P< 0.05.
(C) Same as in (B), but cells were serum-starved for 12 h, either in the absence or presence of 200 nm MLi2 as indicated, and the percentage of ciliated transfected cells
quantified from around 200 cells per condition per experiment. Bars represent mean ± s.e.m. (n=3 experiments); ∗∗∗, P< 0.005; ∗∗ , P< 0.01. (D) Same as (B), with cells
either left untreated or treatedwithMLi2 (200 nm, 12 h) before immunocytochemistry, and the perinuclear accumulation of phospho-T73-RAB10 quantified from around
200 transfected cells per condition and experiment. Bars represent mean ± s.e.m. (n=3 experiments); ∗∗∗∗, P< 0.001; ∗∗∗ , P<0.005. (E) Same as (D), with cells serum-
starved for 12 h either in the absence or presence of 200 nm MLi2 as indicated before immunocytochemistry, and the perinuclear accumulation of phospho-T73-RAB10
quantified from around 200 transfected cells per condition and experiment. Bars represent mean ± s.e.m. (n=3 experiments); ∗∗∗∗ , P<0.001; ∗∗∗, P< 0.005. (F) HEK293T
cells were transfected with the indicated GFP-tagged LRRK2 constructs, extracts analyzed by western blotting for GFP and tubulin as loading control.
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Figure 6. Pathogenic LRRK2 causes phospho-RAB accumulation preferentially in non-ciliated cells and may cause ciliary resorption deficits. (A) HEK293T cells were
co-transfected with pathogenic flag-tagged LRRK2 and smo-EGFP and stained for phospho-T73-RAB10 (secondary Alexa594 antibody, red), pericentrin (secondary
Alexa647 antibody, pseudo-coloured in blue), anti-flag (secondary Alexa405 antibody, pseudo-coloured in cyan) and DAPI (pseudo-coloured in cyan). Example of either
non-ciliated (top) or ciliated (bottom) cell co-expressing smo-EGFP and flag-tagged Y1699C LRRK2. Scale bar, 5 μm. (B) Quantification of the fluorescence intensity of
the phospho-T73-RAB10 accumulation at the ciliary base in cells only expressing smo-EGFP, or co-expressing pathogenic Y1699C LRRK2, according to the absence or
presence of cilia from experiments of the type described in (A). Bars represent mean ± s.e.m. from around 20–30 cells analyzed for each condition; ∗∗∗∗, P< 0.001.
(C) Example of HEK293T cells transfected with GFP-tagged wild-type or Y1699C mutant LRRK2 as indicated and stained for pericentrin, polyglutamylated tubulin and
DAPI. Scale bar, 5 μm. (D) Quantification of the percentage of ciliated cells in either the absence of transfection (ctrl), or upon expression of wild-type or Y1699C mutant
LRRK2 as indicated, which display a duplicated split centrosome phenotype. The centrosomal phenotype was quantified from around 50 ciliated cells per condition
per experiment. Bars represent mean ± s.e.m. (n=3 independent experiments); ∗, P< 0.05.
RILPL1. These data highlight the importance of these proteins in
pathogenic LRRK2 signalling with respect to both ciliogenesis
and centrosomal cohesion (Fig. 9). In the future, it will be
important to determine how pericentrosomal/centrosomal
protein complexes of phospho-RAB8/10 bound to RILPL1 block
cilia formation and interfere with centrosome cohesion.
RAB8 plays an important role in ciliary vesicle trafficking
required for ciliogenesis in a variety of cell types (28,33–37),
whilst the role of RAB10 in primary ciliogenesis remains less
clear (38). Ciliogenesis has been reported to be unimpaired in
mouse embryonic fibroblasts from RAB8A/RAB8B double knock-
out mice but is impaired when additionally silencing RAB10 (27).
These data suggest that RAB10may act synergisticallywith RAB8
in ciliogenesis, such that most ciliary transport processes occur
normally in the absence of RAB8A/B as long as RAB10 remains
available. In contrast, ciliogenesis was reported to be impaired in
A549 RAB8A knockout cells but enhanced in A549 RAB10 knock-
out cells, suggesting that RAB10 may act as a suppressor of cilia
formation (20). Further work is required to understand the rela-
tive contributions of RAB8A/B and RAB10 to ciliogenesis, which
may involve cell type-specific differences in the precise vesic-
ular trafficking steps mediated by these RABs which directly
and/or indirectly impinge upon cilia formation. Importantly, our
data indicate that the pericentrosomal/centrosomal accumula-
tion of phospho-RAB8/10 upon pathogenic LRRK2 expression is
observed in non-ciliated cells but ismuch reduced and/or absent
in ciliated cells. In addition, increasing the levels of phospho-
RAB8/10 by co-expressing the RABswithwild-type LRRK2 caused
a pronounced deficit in ciliogenesis, which was not observed
when expressing either RAB8/10 or wild-type LRRK2 on their
own. Therefore, and apart from a role for endogenous RAB8
and/or RAB10 in regulating ciliary vesicular trafficking events,
our data indicate that the pericentrosomal/centrosomal accu-
mulation of phospho-RAB8/10 interferes with ciliogenesis.
Some proteins implicated in vesicular trafficking events have
been reported to display additional moonlighting functions at
different stages of the cell cycle, including effects on centrosome
cohesion (39).We did not detect centrosomal cohesion deficits in
A549 cells deficient for either RAB8A,RAB10 or RILPL1, indicating
that these three proteins do not modulate centrosome cohe-
sion under normal conditions. However, these three proteins
are crucial for the centrosomal cohesion deficits induced by
pathogenic LRRK2, since LRRK2-mediated deficits were largely
abolished in either A549 RAB8A, RAB10 or RILPL1 knockout cells.
Centrosomal cohesion deficitswere also observedwhen increas-
ing the levels of phospho-RAB8/10 by co-expressing the RABs
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Figure 7. Ciliogenesis deficits in human dermal fibroblasts from G2019S mutant LRRK2 PD patients in contrast to healthy controls. (A) Example of control and G2019S
mutant LRRK2 PD patient fibroblasts stained with polyglutamylated tubulin antibody, pericentrin antibody and DAPI. Scale bar, 10 μm. (B) The percentage of ciliated
cells was quantified from around 100 cells per line, and from 5 control and 5 G2019S mutant LRRK2 fibroblast lines. Control or G2019S mutant LRRK2 fibroblasts were
treated with or without MLi2 (200 nm, 24 h), either in the absence or presence of serum starvation (starv., 48 h) as indicated. Bars represent mean ± s.e.m. (between
five independent lines); ∗∗∗ , P< 0.005; ∗ , P<0.05. (C) High-resolution deconvolved image of a control and G2019S mutant LRRK2 PD patient fibroblast cell stained with
polyglutamylated tubulin antibody, pericentrin antibody and DAPI. Scale bar, 10 μm. (D) Pictures of the type acquired in (C) were analyzed for cilia length as described
in Materials and Methods, with 30–60 ciliated cells analyzed for each cell line. Bars represent mean ± s.e.m. (between five independent lines); ∗ , P< 0.05.
with wild-type LRRK2, but not upon co-expression of phospho-
deficient versions of these RAB proteins. Since phospho-site
RAB8/10 mutants have been reported to be non-functional in
various cellular contexts (11,20), we additionally used LRRK2
kinase inhibitors to demonstrate that the effects were mediated
by the LRRK2 kinase activity. Thus, the pericentrosomal/centro-
somal recruitment of phospho-RAB8/10 is crucial to mediate the
centrosomal cohesion deficits mediated by pathogenic LRRK2 in
a kinase activity-dependent manner.
Overexpression of RILPL1 has been suggested to cause a
deficit in ciliogenesis as well as centrosomal cohesion (20).
This is in contrast to previous studies showing no effect of
RILPL1 overexpression on ciliogenesis (19), and no effect of
RILPL1 overexpression on centrosomal cohesion as determined
in the present study. Further work is needed to corroborate
or refute the effects of increasing cellular RILPL1 levels on
ciliogenesis and/or centrosomal cohesion events. In either case,
loss of RILPL1 abolished the pathogenic LRRK2-mediated deficits
in ciliogenesis (20), and our data show that loss of RILPL1
also abolishes the LRRK2-mediated deficits in centrosome
cohesion. Therefore, this unique effector protein for only the
phosphorylated versions of RAB8/10 plays an essential role in
mediating both centrosome-related cellular readouts.
The observed ciliogenesis deficits in cholinergic neurons in
the striatum of pathogenic LRRK2 mutant mice (20) is expected
to impair a described neuroprotective circuit, whereby Sonic
hedgehog signalling from dopaminergic neurons is sensed by
cilia in the cholinergic neurons, which in turn triggers the
secretion of neuroprotective glial cell line–derived neurotrophic
factor from these cholinergic neurons back towards the
dopaminergic neurons, in this manner maintaining their health
(23). Whilst formal proof for a deficit in this neuroprotective
circuit in the context of pathogenic LRRK2 is currently lacking,
LRRK2-mediated ciliogenesis deficits have also been described
in distinct brain areas of pathogenic LRRK2 knockin mice, and in
various cell types including iPS cells from PD patients based
on LRRK2 mutations, or murine embryonic fibroblasts from
pathogenic LRRK2 knockin mice (20). Additionally, our data
indicate the presence of LRRK2-mediated centrosomal (12) as
well as ciliogenesis deficits in primary dermal fibroblasts from
LRRK2-PD patients, and centrosomal as well as ciliogenesis
defects in astrocytes from pathogenic LRRK2 knockin mice.
Therefore, these pathogenic LRRK2-mediated deficits seem to be
a prominent cellular phenotype observed in a variety of neuronal
and non-neuronal cell types and modulated by LRRK2 kinase
inhibitors. Astrocytes comprise a disease-relevant cell type
which supports the health of dopaminergic neurons (31,32,40),
and aberrant ciliary signalling can affect astrocyte survival under
certain conditions (41). In the future, it will be important to probe
for astrocytic ciliary deficits in the intact rodent and human
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Figure 8. Primary astrocytes from G2019S knockin mice display both centrosomal cohesion and ciliogenesis deficits as in contrast to control astrocytes. (A) Example
of wild-type and G2019S knockin primary astrocytes stained with anti-gamma-tubulin, anti-GFAP and DAPI. Scale bar, 10 μm. (B) Quantification of the percentage of
wild-type or G2019S knockin primary astrocytes with split centrosomes (duplicated centrosomes with a distance between their centres > 1.5 μm), in the presence or
absence of 48 h of serum starvation (S.S.), and in the presence or absence of 200 nm MLi2 for 24 h before immunocytochemistry as indicated. Around 250–350 cells were
quantified per condition per experiment. Bars represent mean ± s.e.m. (n=3 independent experiments); ∗∗∗, P< 0.005; ∗∗ , P< 0.01. (C) Same as in (B), but depicting the
mean distance of duplicated centrosomes. Between 50 and 100 cells with duplicated centrosomes per condition per experiment were analyzed. Bars represent mean
± s.e.m. (n=3 independent experiments); ∗∗∗∗, P< 0.001; ∗∗∗, P<0.005; ∗∗ , P< 0.01; ∗, P<0.05. (D) Example of wild-type and G2019S knockin primary astrocytes stained
with anti-Arl13b, anti-gamma-tubulin, anti-GFAP and DAPI. Scale bar, 10 μm. (E) The percentage of ciliated cells was quantified from around 200 wild-type or G2019S
knockin cells, in either the absence or presence of serum starvation (48 h, S.S.), and absence or presence of 200 nm MLi2 (24 h) as indicated. Bars represent mean ±
s.e.m. (n=3 independent experiments); ∗∗, P< 0.01.
brain and evaluate the possible consequences of such deficits
for dopaminergic cell survival.
Finally, some cells such as microglia or lymphocytes which
express high endogenous LRRK2 levels are largely devoid of a
primary cilium (42,43). However, we have observed centrosomal
cohesion deficits in lymphoblastoid cell lines derived from
LRRK2-PD patients (12). Since our data indicate that the
centrosomal cohesion readout is a reflection of the same
phospho-RAB8/10-RILPL1 mechanism as the one underlying
the LRRK2-mediated ciliogenesis deficits, it will be important
to test in the future whether centrosomal cohesion deficits can
also be observed in primary blood-derived cells from LRRK2-PD
patients, and whether such readout may aid in the stratification
of PD patients who may benefit from LRRK2-related treatment
strategies.
Materials and Methods
DNA constructs and site-directed mutagenesis
GFP-tagged human LRRK2 and RAB8A constructs have been
previously described (12). Myc-DDK-tagged human RAB8B and
human RAB10 were obtained from OriGene, human RILPL1-
DDK was purchased from GenScript, human RILPL1-eGFP
construct was kindly provided by Dr Dario Alessi (University
of Dundee, United Kingdom), and 3×FLAG-tagged human LRRK2
constructs were kindly provided by Dr Elisa Greggio (University
of Padova, Italy). pEGFP-mSmo was a gift from Philip Beachy
(Addgene plasmid 25395) (44). N-terminally GFP-tagged, mRFP-
tagged or 3×FLAG-tagged human RAB8A, RAB8B and RAB10,
and eGFP-tagged human RILPL1 constructs were generated
using Gibson Assembly Master Mix (New England Biolabs).
The RAB8A-C204A, RAB8B-T72A and RAB10-T73A mutations
were generated by site-directed mutagenesis (QuikChange,
Stratagene), and the identity of all constructs verified by
sequencing of the entire coding region. DNA constructs were
prepared from bacterial cultures at 37◦C using PureYieldTM
Plasmid Midiprep System (Promega) following manufacturer’s
instructions.
Cell culture and transfections
HEK293T/17 cells were cultured as previously described (12,45).
Briefly, cells were grown in full medium [Dulbecco’s modified
Eagle’s medium (DMEM) containing low glucose and 10% fetal
bovine serum, non-essential amino acids, 100 U/ml penicillin
and 100 μg/ml streptomycin] and transfected at 80% confluence
with 1 μg of LRRK2 constructs (and 100 ng of RAB constructs
where indicated) with 3 μl of LipoD293TM Transfection Reagent
(SignaGen Laboratories) per well of a 12-well plate for 5 h in
full medium. The next day, cells were split to 25% confluence
onto poly-L-lysine-coated coverslips and subjected to immuno-
cytochemistry or western blot analysis 48 h after transfection.
For ciliogenesis experiments, cells were processed as described
above, and serum starved for 12 h in the absence or presence of
MLi2 (200 nm, 12 h).
HeLa cells were cultured as described (11,46). Briefly, cells
were grown in full medium (DMEM containing high glucose and
10% fetal bovine serum, non-essential amino acids, 100 U/ml
penicillin and 100 μg/ml streptomycin) and transfected at
80% confluence with 200 ng of RAB constructs and 1 μl of
Lipofectamine® 2000 Transfection Reagent (Invitrogen) per well
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Figure 9. Cartoon summarizing pathogenic LRRK2-mediated effects on centrosome cohesion and ciliogenesis. Top row: under normal conditions, RAB8A and RAB10
are localized to the early recycling compartment (ERC), and RILPL1 is localized to the mother centriole (green, with appendages depicted in red). In dividing cells, upon
centriole duplication (daughter centrioles in yellow), the duplicated centrosomes are properly held together in G2 phase by centrosomal linker proteins (red) (left).
Ciliogenesis in interphase or non-dividing cells, nucleated by the mother centriole-derived basal body, occurs normally as well (right). Bottom row: pathogenic LRRK2
phosphorylates RAB8A/RAB10, which causes their relocalization to the centrosome via binding to RILPL1, followed by a deficit in centrosome cohesion in dividing cells
(left), or a deficit in primary cilia formation in interphase or non-dividing cells (right).
of a 12-well plate following manufacturer’s instructions for 5 h
in DMEM. The following day, cells were split 1:3 onto coverslips
and processed for immunocytochemistry 48 h after transfection.
SH-SY5Y cells stably expressing GFP, flag-tagged wild-type
LRRK2, or flag-tagged G2019S-mutant LRRK2 were cultured as
previously described (12,47,48). Briefly, cells were grown in full
medium (DMEM containing high glucose and GlutaMAX (Life
Technologies, 31966-021), supplemented with 15% fetal bovine
serum, non-essential amino acids, 50 μg/ml gentamicin (Life
Technologies) and 200 μg/ml hygromycin B GoldTM (InvivoGen)
and subcultured at a ratio of 1:6 twice a week. Cells were
transfected at 80% confluence in DMEM containing high glucose
and GlutaMAX with 400 ng of RAB constructs and 2 μl of
Lipofectamine® 2000 Transfection Reagent per well of a 24-well
plate, and 5 h later, media was replaced with full medium. Cells
were split 1:3 the following day onto coverslips and subjected to
immunocytochemistry 48 h after transfection.
A549 wild-type cells, as well as CRISPR/Cas9 A549 RAB8A
knockout, RAB10 knockout and RILPL1 knockout cells were gen-
erously provided by D. Alessi (2,20,49). Cells were cultured in
DMEM containing high glucose without glutamine and sup-
plemented with 10% fetal bovine serum, 2 mm L-glutamine,
100 U/ml of penicillin and 100 μg/ml of streptomycin and subcul-
tured at a ratio of 1:6–1:10 twice a week. Cells were transfected
at 90% confluence with 1 μg of LRRK2 constructs and 4 μl of
LipoD293TM Transfection Reagent (SignaGen Laboratories), and
5 h later, media was replaced with full medium. Cells were split
1:4 onto coverslips the following day and processed for immuno-
cytochemistry or western blotting 48 h after transfection.
Primary human skin fibroblasts established from skin biop-
sies taken from five age- and sex-matched healthy controls
and five PD patients with the G2019S mutation (12,46), with
informed consent and ethical approval, were grown in Iscove’s
modified Dulbecco’s media (IMDM) and 10% fetal bovine serum,
with media exchanged every 2 days. Cells were subcultured at
a ratio of 1:4 and seeded at equal densities onto coverslips. For
ciliogenesis experiments, cells were serum-starved for 48 h in
either the presence or absence of 200 nm MLi2 for the last 24 h.
Analyses were carried out on passages 5–10, with no passage-
dependent differences observed.
Heterozygous breeding pairs of mice were crossed to yield
wild-type and homozygous G2019S progeny, which were then
bred to obtain homozygous embryonic wild-type or G2019S
knockin pups (30). Mouse cortical astrocytes from wild-type or
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homozygous G2019S knockin mice were cultured as previously
described (50). Briefly, 6–7 brains were obtained from P1 to P4
mouse pups; isolated cortices were mechanically dissociated in
BME, and dissociated cells cultured in growth medium [DMEM
with pyruvate, high glucose (Life Technologies, 41966-029) and
10% fetal bovine serum (HyClone Fetal Bovine Serum, Fisher,
10309433)]. Cells were seeded in two 175 cm2 cell culture flasks,
and the following day, old growth medium was removed and
replaced with fresh ice-cold growth medium. Four days later,
this procedure was repeated, and subsequently, 50% of growth
medium was replaced with warm growth medium every 3–
4 days. Once confluent, cells were split at high density onto
poly-L-lysine (Sigma, P9155)-coated coverslips and processed
for immunocytochemistry. For ciliogenesis, cells were serum-
starved for 48 h, in the presence or absence of 200 nm MLi2 for
the last 24 h.
Where indicated, cells were treated with MLi2 (MRC PPU,
Dundee, UK) or GSK2578215A (Tocris) before fixation.
Immunocytochemistry
For centrosome staining, HEK293T/17 and A549 cells were
fixed with 2% paraformaldehyde (PFA) in PBS for 20 min
at room temperature, whilst SH-SY5Y cells were fixed with
2% PFA in PBS containing 4% sucrose for 20 min at room
temperature. For detection of primary cilia in HEK293T/17,
and primary cilia and centrosomes in primary dermal human
fibroblasts and astrocytes, cells were fixed with 4% PFA
in PBS for 15 min at 37◦C, followed by ice-cold MeOH for
5 min. In all cases, cells were permeabilized with 0.2%
Triton-X100/PBS for 12 min at room temperature, followed by
incubation in blocking solution (0.5% BSA (w/v) in 0.2% Triton-
X100/PBS) for 1 h at room temperature. Primary antibodies were
diluted in blocking solution and incubated overnight at 4◦C.
Primary antibodies included rabbit polyclonal anti-pericentrin
(Abcam, ab4448, 1:1000), mouse monoclonal anti-pericentrin
(Abcam, ab28144, 1:1000), mouse monoclonal anti-γ -
tubulin (Abcam, ab11316, 1:1000), mouse monoclonal anti-flag
(Sigma, clone M2, F1804, 1:500), rabbit monoclonal knockout-
validated anti-RAB8A (Abcam, ab188574, 1:1000), mouse mon-
oclonal knockout-validated anti-RAB10 (Sigma, SAB5300028,
1:1000), mouse monoclonal anti-polyglutamylated tubulin
(AdipoGen, AG-20B-0020-C100, 1:1000), rabbit polyclonal anti-
Arl13b (ProteinTECH, 17711-1-AP, 1:250), chicken polyclonal
anti-GFAP (Abcam, ab4674, 1:500) and mouse monoclonal
p230/Golgin245 (BD, 611280, 1:400). The sheep anti-RAB8A (MRC
PPU, S969D, 1:250), anti-phospho-T72-RAB8A (MRC PPU, S874D,
1:50), anti-RAB10 (MRC PPU, S945D, 1:250) and anti-phospho-T73-
RAB10 (MRC PPU, S873D, 1:50) have been previously described (3)
and were generously provided by D. Alessi . The sheep phospho-
T72-RAB8A and phospho-T73-RAB10 antibodieswere used in the
presence of a 10-fold molar excess of the respective dephospho-
peptides, or of the respective phospho-peptideswhere indicated.
Importantly, all double- and triple-immunocytochemistry
involving sheep antibodies were performed sequentially, with
the sheep antibody employed first, and omitting the MeOH
fixation step. The rabbit polyclonal anti-phospho-T72-RAB8A
and rabbit polyclonal anti-phospho-T73-RAB10 antibodies were
kindly provided by D. Alessi and employed at a dilution of 1:250.
The rabbit monoclonal knockout-validated anti-phospho-T72-
RAB8A (Abcam, ab230260) was used at a dilution of 1:1000.
For the rabbit monoclonal knockout-validated anti-phospho-
T73-RAB10 (Abcam, ab230261, 1:1000) antibody, 0.2% Triton-
X100/PBS was replaced by 0.1% saponin/PBS throughout. The
following day, coverslips were washed two times 10 min in 0.2%
Triton-X100/PBS (or 0.1% saponin/PBS) (wash buffer) and were
incubated with secondary antibodies diluted in wash buffer for
1 h at room temperature.
Note that the sheep total anti-RAB8A and total anti-RAB10
antibodies have been previously validated against extracts from
RAB8A or RAB10 A549 knockout cell lines (MRC PPU, Dundee,
UK). The commercial mouse total anti-RAB8A antibody has
been previously validated against extracts from a RAB8A HAP1
knockout cell line (Abcam, ab188574), and the commercial
mouse total anti-RAB10 antibody has been previously validated
against HELA cell extracts in the presence or absence of
siRNA of RAB10 (Sigma, SAB5300028/Thermo Fisher, MA5-15670,
clone 4E2). The sheep phospho-RAB8A and phospho-RAB10
antibodies have been previously validated in HEK293 cells
overexpressing the respective RABs in the presence or absence
of a LRRK2 kinase inhibitor, as not sensitive enough to detect
endogenous phospho-RAB levels by western blotting techniques
(6). The rabbit monoclonal phospho-RAB8A and phospho-RAB10
antibodies are able to detect endogenous phospho-RABs by
western blotting techniques and have been previously validated
by western blotting using both LRRK2 knockout mice extracts,
as well as A549 RAB8A or RAB10 knockout cell extracts (6).
Secondary antibodies included Alexa405-conjugated goat
anti-mouse, Alexa488-conjugated goat anti-mouse, goat anti-
rabbit or donkey anti-sheep, Alexa555-conjugated goat anti-
mouse or goat anti-rabbit, Alexa594-conjugated goat anti-
mouse, goat anti-rabbit or donkey anti-sheep, Alexa647-
conjugated goat anti-mouse, goat anti-rabbit or donkey anti-
sheep (all from Invitrogen, 1:1000). Alexa405-conjugated goat
anti-chicken was from Abcam (ab175675, 1:250). Coverslips were
washed two times in wash buffer, rinsed in PBS and mounted in
mounting medium with DAPI (Vector Laboratories).
For the determination of the subcellular localization of GFP-
tagged RAB proteins in HeLa cells, cells were transfected and
cultured as described above and fixed 48 h after transfection
with 4% PFA/PBS for 20 min at room temperature. Coverslips
were washed with PBS and mounted with mounting medium
with DAPI.
Image acquisition and quantification
Images were acquired on a Leica TCS-SP5 confocal microscope
using a 63× 1.4 NA oil UV objective (HCX PLAPO CS). Images were
collected using single excitation for each wavelength separately
and dependent on secondary antibodies [488 nm argon laser
line and a 510–540 nm emission band pass, 543 HeNe laser line
and a 555–575 nm emission band pass (for Alexa555) or a 590–
620 nm emission band pass (for Alexa594), 633 nm HeNe Laser
line and a 640–670 nm emission band pass]. GFP-tagged proteins
were excited with a 488 nm argon laser line and a 500–530 nm
emission band pass, mRFP-tagged proteins were excited with a
543 nm HeNe laser line and a 560–590 nm emission band pass,
and DAPI with a 405 nm UV diode and a 430–470 nm emission
band pass, respectively.
For centrosome cohesion determination, 10–15 image
sections of selected areas were acquired with a step size of
0.5 μm, and z-stack images analyzed and processed using Leica
Applied Systems (LAS AF6000) image acquisition software. The
same laser intensity settings and exposure times were used for
image acquisition of individual experiments to be quantified.
For HEK293T/17 cells and SH-SY5Y cells, centrosomes were
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scored as being separated when the distance between their
centres was >1.5 μm (12). For A549 cells, the mean distance
between duplicated centrosomes was 1.49±0.13 μm (mean ±
s.e.m., n=82 cells), and duplicated centrosomes were scored as
separated when the distance was >2.5 μm. For mouse cortical
astrocytes, the mean distance between duplicated centrosomes
was 1.18±0.06 μm (mean ± s.e.m., n=96 cells), and duplicated
centrosomes were scored as separated when the distance was
>1.5 μm. In all cases, mitotic cells were excluded from the
analysis.
Quantification of phospho-RAB10 signal in SH-SY5Y or
HEK293T/17 cells was performed over non-processed and non-
saturated images acquired on the same day and with the same
laser intensities with Leica Applied Systems (LAS AF6000) Image
Acquisition Software. Circular ROIs of 3 μm diameter were set
on top of the centrosome signal as detected by anti-pericentrin
staining, and the mean intensity from the phospho-RAB10
signal obtained from 50–70 cells per condition and experiment.
Background signal was subtracted in all cases by placing the ROI
in a different aleatory place within the same cell.
For determination of the percentage of ciliated cells, cells
were visualized on an inverted microscope (Zeiss) using a 100×
1.4 NA Plan APO oil objective. For each experiment, around 200
random cells were scored for either the presence or absence of
primary cilia as assessed by either polyglutamylated tubulin or
Arl13b staining, with identical results obtained in both cases.
Quantification of the percentage of ciliated cells was performed
by two additional observers blind to condition, with identical
results obtained in all cases. As an additional means of primary
cilia quantification, 20–25 image sections were acquired with a
step size of 0.25 μm, and images deconvolved using Huygens
Essential Deconvolution Software. For measuring cilia length, a
method based on the Pythagorean theorem (PyT) was employed,
and around 40 cells per condition were quantified (51,52). Cilia
length was also quantified based on maximum intensity projec-
tion (MIP), with the determined cilia length smaller as expected
(52), but with no difference between genotypes observed.
Western blotting
HEK293T/17, A549 and HeLa cells were collected 48 h after trans-
fection from awell of a 6-well plate, washed in PBS, resuspended
in 75 μl of PBS, lysed with 25 μl of 4× Nu PAGE LDS sample
buffer (Novex, Life Technologies, NP00008) supplemented with
β-mercaptoethanol to a final volume of 2.5% (v/v) and sonicated
and boiled at 70◦C for 10 min. Around 10–15 μl (around 20 μg
of protein) were resolved by SDS-PAGE polyacrylamide gel
electrophoresis using 4–20% precast gradient gels (Bio-Rad,
456-1096), and proteins electrophoretically transferred onto
nitrocellulose membranes (GE Healthcare). Membranes were
blocked in blocking buffer (Li-COR Biosciences, Li-COR Odyssey
PBS blocking buffer, 927-40000) for 1 h at room temperature and
incubated with primary antibodies in blocking buffer overnight
at 4◦C. Primary antibodies included rabbit polyclonal anti-GFP
(Abcam, ab6556, 1:1000), mouse monoclonal anti-flag (Sigma,
clone M2, F1894, 1:500), rabbit monoclonal knockout-validated
anti-RAB8A (Abcam, ab188574, 1:1000), mouse monoclonal
anti-RAB8(A+B) (BD, 610844, 1:500), rabbit polyclonal anti-
RAB8B (Invitrogen, PA5-67354, 1:1000), mouse monoclonal
knockout-validated anti-RAB10 (Sigma, SAB5300028, 1:1000),
rabbit monoclonal anti-phospho-T72-RAB8A (Abcam, ab230260,
1:1000), rabbit monoclonal anti-phospho-T73-RAB10 (Abcam,
ab230261, 1:1000), rabbit monoclonal anti-phospho-S935-LRRK2
(Abcam, ab133450, 1:500), mouse monoclonal anti-α-tubulin
(Sigma, clone DM1A, T6199, 1:25 000) and mouse monoclonal
anti-GAPDH (Santa Cruz, sc-32 233, 1:2000). Secondary antibodies
included goat anti-rabbit or anti-mouse IRDye 800CW, and goat
anti-rabbit or anti-mouse IRDye 680CW (1:14 000). Blots were
imaged via near infrared fluorescent detection using Odyssey
CLx Imaging System, and quantification was done using the
instrument’s Image Studio Software.
For sheep antibodies, HEK293T/17 and A549 cells were col-
lected 48 h after transfection, washed in PBS, resuspended in
80 μl of PBS and lysed with 20 μl of 5× Laemmli SDS sample
buffer supplemented with β-mercaptoethanol (final 2.5% (v/v)).
Extracts were sonicated and boiled at 95◦C for 5 min. Proteins
were resolved by SDS-PAGE polyacrylamide gel electrophoresis
and transferred onto nitrocellulose membranes as described
above. Membranes were blocked in 5% milk in 0.1% Tween-
20/TBS for 8 h, and primary antibodies diluted in 5% milk in
0.1% Tween-20/TBS and incubated overnight at 4◦C. Antibodies
included sheep anti-RAB8A and anti-phospho-T72-RAB8A (MRC
PPU, S969D and S874D, 1:500 and 1:250, respectively), sheep
anti-RAB10 and anti-phospho-T73-RAB10 (MRC PPU, S945D and
S873D, 1:500 and 1:250, respectively) and sheep anti-RILPL1 (gen-
erously provided by D. Alessi). Membranes were washed three
times in 0.1% Tween-20/TBS, followed by incubation with HRP-
conjugated rabbit anti-sheep secondary antibodies diluted in
5% milk in 0.1% Tween-20/TBS for 1 h. Western blotting of
sheep antibodies was performed with ECL Prime Western Blot-
ting Detection Reagent (GE Healthcare).
Statistical analysis
One-way ANOVA with Tukey’s post hoc test was employed, with
significance set at P<0.05. Significance values for all data are
indicated in figure legends. All statistical analysis and graphs
were performed using Prism software version 7.0 (GraphPad, San
Diego, CA).
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